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the medical system. Previously, therapy has improved symptoms while leaving the patient disabled in the 
later stages. Renal denervation (RDN) is a procedure that is being researched for its effect on improving 
the condition of heart failure along with its symptoms and increasing exercise tolerance in patients. 
Methods: Exhaustive search of available medical literature using MEDLINE via PubMed, CINAHL, Web of 
Science and Google Scholar using the keywords renal denervation, heart failure and exercise tolerance. 
The studies that fit the eligibility criteria were appraised with the GRADE system for quality. 
Results: Three studies were considered after the exclusion criteria were applied. The first study assessing 
RDN for patients with heart failure was terminated early due to low recruitment. Another study by the 
same group showed that RDN was a promising treatment needing more research and clinical evidence. 
The most recent study, an RCT, found that RDN safely improved cardiac function and exercise tolerance in 
patients with heart failure. 
Conclusion: RDN does improve exercise tolerance in patients with heart failure. More clinical evidence is 
needed to place this treatment in common practice but RDN should be considered when reviewing 
options for patients with heart failure. 
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Abstract  
Background: Heart Failure is a growing clinical syndrome that results in major impacts 
on patients and the medical system. Previously, therapy has improved symptoms while 
leaving the patient disabled in the later stages. Renal denervation (RDN) is a procedure 
that is being researched for its effect on improving the condition of heart failure along 
with its symptoms and increasing exercise tolerance in patients. 
Methods:  Exhaustive search of available medical literature using MEDLINE via 
PubMed, CINAHL, Web of Science and Google Scholar using the keywords renal 
denervation, heart failure and exercise tolerance. The studies that fit the eligibility criteria 
were appraised with the GRADE system for quality. 
Results:  Three studies were considered after the exclusion criteria were applied.  The 
first study assessing RDN for patients with heart failure was terminated early due to low 
recruitment. Another study by the same group showed that RDN was a promising 
treatment needing more research and clinical evidence. The most recent study, an RCT, 
found that RDN safely improved cardiac function and exercise tolerance in patients with 
heart failure. 
Conclusion:  RDN does improve exercise tolerance in patients with heart failure. More 
clinical evidence is needed to place this treatment in common practice but RDN should 
be considered when reviewing options for patients with heart failure. 
Keywords:  Renal denervation, heart failure and exercise tolerance 
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BP Blood pressure 
EF      Ejection fraction 
HF      Heart failure 
RDN Renal denervation 
HFpEF Heart failure with preserved ejection fraction 
HFrEF Heart failure with reduced ejection fraction 
NT-proBNP N-terminal pro B-type natriuretic peptide
SNS Sympathetic nervous System 
T1DM Type 1 diabetes mellitus 
UFH Unfractionated heparin 
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The Effect of Renal Denervation on Exercise Tolerance 
in Patients with Heart Failure 
BACKGROUND 
Heart Failure (HF) is a clinical syndrome that has major impacts on patients, 
families, practitioners, resources and the medical system. Clinical Key defines HF as a 
clinical syndrome characterized by structural or functional impairment of ventricular 
filling or ejection of blood resulting in insufficient perfusion to meet metabolic demands.1 
Cardinal manifestations include edema, dyspnea, and fatigue. Its later stages, HF severely 
impacts quality of life and exercise tolerance. Lack of exercise tolerance can make 
activities of daily living (ADL) impossible and is an important patient centered outcome 
that should be considered when implementing various treatments. 
There are many ways to categorize HF and this paper will look at studies 
addressing many types. Heart failure with preserved ejection fraction (HFpEF) is a form 
of diastolic dysfunction which is often caused by ventricular hypertrophy due to long 
standing hypertension. Heart failure with reduced ejection fraction (HFrEF) is the more 
common subtype of HF commonly occurring in the presence of coronary artery disease. 
This type of HF is due to ventricular dilation resulting in an inadequate pump.1
There are many complications including arrhythmia and risk of 
thromboembolism. The treatment of HF is mainly pharmacologic and palliative in its end 
stages.1  With standard treatment, often the functional status declines and the only benefit 
is seen in symptom control. Much focus has been placed on improving outcomes due to 
the significant patient impacts and the burden to the health care system. The rates of re-
hospitalization are also placing burden on the health system and new treatments may help 
curb this problem for the patient and the system. This review aims to evaluate the effect 
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on exercise tolerance in patients with HF by using Renal Denervation (RDN) for 
treatment. 
RDN is a procedure that uses ablation of the renal nerve to dampen the effects of 
the sympathetic nervous system. This procedure has been studied for its effects in HTN 
but shows promise in the hormonal regulation of HF.2 The procedure has changed as the 
equipment and technique advances but access is commonly through the femoral region 
with a sheath inserted to pass a catheter through. As seen in the First-in-man safety 
evaluation2 of RDN, the procedure was safely performed in 7 patients with no pre or post 
procedural complications noted. 
METHODS 
An exhaustive search was performed using MEDLINE via PubMed, CINAHL, 
Web of Science and Google Scholar using the keywords renal denervation, heart failure 
and exercise tolerance. Inclusion criteria consisted of patients with heart failure receiving 
RDN for treatment. Exclusion criteria consisted of human studies and english language 
only. As a note, this author chose to use RDT for renal denervation treatment where 
studies use various abbreviations. In addition, this review looks at studies assessing 
HFpEF, HFrEF or HF unspecified. Studies were assessed for quality using GRADE 
criteria.3 
RESULTS 
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Of 278 studies produced by a search of the keywords, 3 fit all criteria and were 
included in this review. The 3 studies4-6 were evaluated with the GRADE criteria and 
ranked accordingly. See Table 1. 
Patel et al 
This study4 was a prospective phase II RCT which aimed to provide the first 
human data concerning RDN as a treatment for HFpEF by dampening the effects of the 
SNS. After screening 10,228 patients, 25 were randomized with 17 being allocated to 
receive bilateral RDT via the SymplicityTM catheter with 8 patients as a control.  At 12 
months, 14 in the treatment group had complete data as well as 7 in the control group. 
Four months after the trial start date, the protocol was adjusted to ensure proper 
recruitment. This adjustment allowed for patients who had not been previously 
hospitalized for HF to participate and decreased the EF from >50% to >40%. Computer 
randomization was utilized with no patient or clinician blinding due to the study being 
focused on safety and mechanism.4  
There were 6 efficacy endpoints consisting of: “the Minnesota Living with Heart 
Failure Questionnaire (MLWHFQ); peak treadmill exercise oxygen uptake (VO2 peak); 
B-type natriuretic peptide (BNP); E/e′ (ratio of early mitral out ow velocity to average of
medial and lateral mitral annular tissue velocity); left atrial volume index [LAVi from 
cardiac magnetic resonance (CMR)] and LV mass index (LVMi from CMR).”4  Twenty-
five patients were enrolled in the study which ended after 16 months due to low 
recruitment. Some initial improvements in various endpoints in the RDT group was noted 
at the 3 month mark with no significant improvement at 12 months.4 
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 This study4  did not show benefit to the patient nor did it show harm and was 
ended early secondary to recruitment issues. As for the improvements noted at 3 months, 
the authors have discussed a few potential reasons with one being the Hawthorne effect 
which is when the patient knows they have received the treatment and therefore might try 
harder upon testing for effect.  The author notes this effect is likely to wane over time. In 
addition, the possibility of a type 1 error is possible or the potential re-growth of the 
sympathetic nerve function. At the 12 month mark, the lack of improved endpoints were 
thought to be caused by under recruitment and exposing the study to a type II error. 
While the inclusion criteria were changed 4 months into the study, enough patients were 
not involved and the next effort should draw on heart failure patients around the world to 
ensure proper recruitment. The authors mention the catheter used, SymplicityTM, could be 
an ineffective tool for ablation or that focusing on the distal portion of the renal artery 
may have more of an effect suppressing SNS activity.4  
Gao et al (2016) 
 This non-blinded study5 published in 2016 was attempted after the study group 
showed improvement in cardiac function and reduction in LV volume using a Medtronic 
Inc. 5F ablation catheter in pigs. The study group decided to move to a human trial 
including 14 patients. This prospective study was open and without a control group. “The 
inclusion criteria were a diagnosis of CHF; EF <45% on echocardiography; >2 HF 
episodes in the previous six months; medication with HF drugs including beta- blockers, 
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blocker 
(ARBs) and spironolactone; and no acute HF decompensation in at least one month of 
drug therapy.”  Patients with evidence of renal artery stenosis, GFR <30ml/min/1.73m2, 
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T1DM, pregnancy or possibility of, MI or CVA (acute) or hypotension as indicated by 
systolic BP <100 mmHg were excluded from this study.5 
 All patients in the study were given chewable enteric coated aspirin or clopidogrel 
(300Mg both) and IV unfractionated heparin (6000-8000 U) prior to the procedure. All 
patients were evaluated for BP and 6-min walk distance before the intervention, at 7 days 
post intervention and every month thereafter to the study’s conclusion. In addition, 
patients were assessed for renal artery stenosis via ultra sound pre procedure and with 
echo and blood work at the six-month follow up. All patients were continued on their 
maximum tolerated doses of HF medications and adjusted as needed.5  
 The procedure itself was performed using a 5F radiofrequency catheter with a 
39D72X Stockert EP Shuttle RF Generator (Johnson & Johnson Medical) with 
temperature control (8-10 W, 50◦C) for rotational ablation. Immediately after bilateral 
ablation of 4-6 sites was performed, renal angiography was used.5 
 At the 6-month follow up there were noted decreases in BP (Systolic average 
138.6 at baseline and 123.2 at follow up). Four patients started with NYHA functional 
class of IV with none in this class at six months. Ten patients started in class III and at the 
six-month evaluation only 1 remained in class III, 9 in class II, and 4 in class I. BNP 
levels dropped, on average, 361 points from baseline at 6 months. The patients in this 
study showed an average increase of 169m in the 6-minute walk test.5  
 This study5 showed improvement in exercise tolerance and 6-minute walk 
distance. Gao et al (2016) state that using the larger catheter (5f) instead of smaller 
catheters used in the past likely led to the better penetration of vessels. This new catheter 
along with a refined technique may be responsible for the improvement of EF and left 
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ventricular volume as shown by echocardiography in this study. This study5 also shows 
that RDN may be more useful for patients with hypertensive heart failure due to the SNS 
activity decrease and its effects on BP.5  
 The authors of this study5 conclude that “RDN using a 5F ablation catheter can 
improve cardiac function, reduce HF symptoms and signs, and enhance exercise 
tolerance in patients with HF” however a larger scale study should be performed to 
confirm these findings.  
Gao et al (2018) 
 This most recent study6 was single-centre, prospective, randomized and controlled 
study. This study was performed by 3 of the authors in the previous Gao et al (2016) 
study.5 This study looked at patients with chronic systolic HF and targeted the role of 
excess SNS activity. This study enrolled 60 patients to randomly receive RDN or to be in 
the control group. “All patients performed a 6-minute walk test, echocardiography, blood 
pressure measurement, and biochemical test, at both baseline and in a 6-month follow 
up.” Patients with renal artery stenosis, TIDM, recent MI or CVA(6 months), possible 
pregnancy or severe valvular heart disease were excluded from this study. Patients were 
included if they had NYHA functional class II or III chronic systolic HF. Patients 
included were over 18 years of age, had LVEF <40% on echocardiography or NT-
proBNP > 125 pg/mL, GFR >45 mL/min/1.73 m2 and systolic BP >100mmHg.6 
 This study6 randomized 30 patients to receive RDN and they were pre-treated 
with chewable enteric coated aspirin 300 mg or clopidogrel 300mg. The patients were 
also given IV heparin 6000-8000 U. The catheter used in this study was a “6 F 
radiofrequency ablation catheter (Ablation instrument [39D-72X]: Johnson Medical 
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Instrument Co. Ltd.) in temperature control mode (8–10 W, 50°C).” After the procedure 
patients were evaluated with renal arteriography. All patients were kept on their current 
medication regimen with maximum tolerated doses and after ablation, meds were 
adjusted according to common practice.6  
 Patients were followed for 6 months post procedure and efficacy and safety 
endpoints were followed through this time. The efficacy endpoints were LVEF (via 
echocardiography), NT-proBNP level, NYHA class and six-minute walk test. Of these 
endpoints, all parameters showed improvement. Distances in the 6-minute walk test 
increased by 75 meters on average which is estimated from figure 3 in the study.6 The 
safety endpoints of GFR, BP and heart rate showed no significant changes and no 
procedure driven incidents occurred. The authors of this study conclude that RDN is an 
effective and safe treatment for HF and especially the treatment of HF in the setting of 
HTN.6 
 
 
 
 
DISCUSSION 
 
 The studies4-6 have shown promise of RDN as a treatment for HF. The results 
collectively showed improvement across a wide range of endpoints and lacked significant 
issues of safety. The data compiled should be enough to set in motion a larger study to 
truly capture the effect of RDN on the patient and exercise tolerance. 
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 This is an exciting time in the course of RDN research. While the results for its 
effect on hypertension (HTN) has not shown significant benefit, the previous research has 
solidified the safety of the treatment even if it is used for a relative disease process. Even 
better, if we are able to use RDN in common practice with greater benefit being in 
patients with concomitant HTN, then the past research for its use in HTN serves an even 
greater purpose.  
 There could be apprehension from researchers to proceed with full motion into 
trials of RDN for HF due to the experiences had with HTN. This may lead to a delay in 
studies being performed or bias in some way. On the other hand, this is promising 
research and will hopefully lead the charge into a larger study being conducted.  
 Many benefits in biochemical markers, exercise tolerance, and changes in NYHA 
functional class have been shown in the studies reviewed here. If these results could be 
shown over the long term and with a larger sample size then this may just be a way to 
treat past the symptoms and lessen some of the disability that comes with advanced heart 
failure.  
 
CONCLUSION 
 RDN is a potential treatment for increasing exercise tolerance in patients with HF. 
Hopefully, the lack of benefit shown in patients with HTN will not steer research away 
from RDN. The research in this realm is too young to be able to recommend RDN as a 
mainstream treatment. With enough clinical evidence, this could be a beneficial option 
for patients with HF and especially with a hypertensive variety. Further clinical research 
  - 14 -  
is needed to determine the efficacy of RDN in patients with HF but this treatment should 
be considered in the appropriate settings. 
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Table 1: Quality Assessment of Reviewed Articles 
Study 
Desi
gn 
Downgrade Criteria 
Upgrade 
Criteria 
Qualit
y Limitati
ons 
Indirectn
ess 
Inconsist
ency 
Imprecis
ion 
Publication 
bias 
Patel et 
al4 
RCT Seriousa Not 
Serious 
Not 
Serious 
Not 
Serious 
Likelyb none Low 
Gao et al 
(2016)5 
Coh
ort 
Seriousc Not 
Serious 
Not 
Serious 
Not 
Serious 
Unlikely none Very 
Low 
Gao et al 
(2018)6 
RCT Not 
Serious 
Not 
Serious 
Not 
Serious 
Not 
Serious 
Unlikely  none High 
a There was no patient or provider blinding. 
b The Patel et al was partially funded by Medtronic who developed the catheter used in the 
study. 
c Study lacks control group and blinding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
